Product Usage: Our peptides are for in vitro research purposes only and are not for human consumption. The statements made within the website have not been evaluated by the USA Food and Drug Administration.
Semaglutide 2 mg — 5 Vial Research Package
Semaglutide 2mg 5 Vials is a lyophilized research peptide package for qualified laboratory research only. The key buying details are simple: 5 vials, 10mg per vial, $207.35 total, and $41.47 per vial.
- Verification: current COA, HPLC, and MS documents are displayed on the product page.
- Purity context: the current page provides COA and HPLC documents; review those files directly for the batch-specific purity result.
- Shipping: $14.99 USPS Priority shipping is standard; see the shipping policy.
- Use boundary: research use only; not for human or animal use.
Quick Facts & Key Specifications
This section answers the first scan question: what is being offered, in what format, and what documentation supports the product record?
| Product | Semaglutide 2mg 5 Vials |
|---|---|
| SKU | S0034-2-1 |
| Categories | Semaglutide; Peptides; Research Chemical |
| Tags | peptides; semaglutide; Semaglutide 2mg |
| Package format | 5 vials; 2mg per vial; lyophilized peptide material |
| Price context | $207.35 package total; $41.47 per vial |
| Purity context | Review the current COA and HPLC documents for the batch-specific purity result |
| Identity context | Modified 31-amino-acid GLP-1 analog with Aib substitution and C18 fatty-diacid modification |
| Verification | COA, HPLC, and MS documentation displayed on this page |
| Use boundary | Laboratory research only; not for human or animal use |
What Is This Peptide?
Semaglutide is a synthetic, long-acting analog of human glucagon-like peptide-1 designed for GLP-1 receptor research. It contains 31 amino-acid residues with structural modifications that increase resistance to enzymatic degradation and promote albumin association.
Lyophilized Semaglutide may appear as a fine white powder, porous cake, or compact peptide puck adhered to the vial surface. These visual differences can arise from freeze-drying conditions and do not replace batch-specific analytical documentation.
History & Research Background
Semaglutide was developed from the GLP-1 analog research programme as a longer-acting peptide with an Aib substitution at position 8, an amino-acid substitution at position 34, and a C18 fatty-diacid side chain attached through a linker. These modifications were designed to reduce DPP-4 degradation and increase albumin binding.
The scientific record includes receptor pharmacology, pharmacokinetic studies, metabolic research, and extensive controlled human trials. Those data concern regulated pharmaceutical formulations and do not authenticate independently sourced research material.
Research Snapshot: Current State of Research
Semaglutide has been examined extensively in GLP-1 receptor pharmacology, glucose-regulation research, appetite and gastric-emptying studies, cardiovascular-outcome research, body-weight trials, kidney-outcome research, and peptide-formulation studies.
Dominant evidence type
Receptor pharmacology, preclinical studies, pharmacokinetics, and large randomized human trials involving approved pharmaceutical formulations.
Frequently studied themes
GLP-1 receptor signalling, glucose-dependent insulin secretion, appetite, gastric emptying, body weight, cardiovascular outcomes, kidney outcomes, and tolerability.
Evidence boundary
Clinical evidence does not validate an independent research batch. COA, HPLC, and MS remain necessary for batch-level review.
- PubMed PMID 29651726 — cardiovascular outcomes with injectable Semaglutide.
- PubMed PMID 33567185 — randomized obesity trial.
- PubMed PMID 37952131 — cardiovascular outcomes in adults with overweight or obesity.
- PubChem CID 56843331 — compound identity record.
Research Models & Proposed Pathways
Semaglutide primarily acts through GLP-1 receptor agonism. Interpretation depends on formulation, exposure, route, population, and the exact endpoint studied.
| Research area | Examples of studied endpoints | Interpretive boundary |
|---|---|---|
| GLP-1 receptor signalling | cAMP signalling, receptor activation, insulin secretion, and glucagon-related endpoints | Receptor activity does not independently establish a clinical result |
| Gastrointestinal physiology | Gastric emptying, appetite-related measures, nausea, vomiting, and satiety endpoints | Effects vary with exposure, formulation, and study design |
| Metabolic research | Glucose, HbA1c, body weight, lipids, waist circumference, and liver-related endpoints | Clinical outcomes apply to the tested pharmaceutical formulation and protocol |
| Cardiovascular and kidney research | Major cardiovascular events, kidney outcomes, blood pressure, and related biomarkers | Outcome-trial findings cannot authenticate an independent research batch |
| Analytical characterisation | Modified sequence, acylation, purity, related peptides, mass, and degradation products | HPLC alone does not confirm full modified-peptide identity |
Evidence Level & Research Limitations
Semaglutide has a mature evidence base that includes receptor pharmacology, pharmacokinetics, and large randomized human trials. That evidence concerns regulated pharmaceutical products and does not eliminate the need for direct research-batch verification.
Key limitations to disclose
- Approved pharmaceutical products and independently sourced research material are not interchangeable.
- Clinical results depend on formulation, route, dose schedule, population, and monitoring.
- Product-specific identity, acylation, purity, potency, sterility, endotoxin status, and traceability require direct review.
- HPLC area percentage does not establish complete modified-peptide identity or biological potency.
- Analytical purity does not establish clinical suitability, safety, or effectiveness.
Common Misconceptions
| Misconception | More accurate interpretation |
|---|---|
| “Published Semaglutide trials validate every vial sold under that name.” | Clinical trials used controlled pharmaceutical material. Independent research batches require separate identity and purity verification. |
| “Semaglutide is identical to native GLP-1.” | It is a modified analog with substitutions and a fatty-diacid side chain. |
| “A high HPLC result proves correct GLP-1 receptor activity.” | HPLC supports chromatographic purity, not complete identity, potency, sterility, or receptor function. |
| “Approved medicines and research material are interchangeable.” | They differ in manufacturing controls, formulation, regulatory status, testing, and intended use. |
| “A COA is the same as regulatory approval.” | A COA is a batch document, not approval for human or animal use. |
Future Research Directions
Current research continues to examine long-term cardiovascular and kidney outcomes, broader populations, neurological and addiction-related hypotheses, combination approaches, oral delivery technologies, immunogenicity, formulation stability, degradation pathways, and analytical methods for modified peptide products.
Testing & Verification: HPLC, LC-MS/MS, COA, and Why Both Matter
This section answers how to read the testing stack. A COA summarizes batch-level information, HPLC gives chromatographic purity context, and MS or LC-MS/MS supports identity review through mass-based evidence.
COA
Connects the product record to a batch, reported purity, and document date.
HPLC
Shows separated peaks under the stated method and gives context for the listed purity figure.
LC-MS/MS / MS
Supports identity review by comparing mass-based evidence against the expected Semaglutide peptide.
Why both matter: purity and identity are not the same measurement. HPLC can support a purity claim, while MS or LC-MS/MS supports identity context; together with the COA, they create a stronger analytical record.
Quality Assurance & Batch Documentation
This section keeps current batch evidence in one place. The same three USCL 073125 PDFs are also retained in the product tabs.
| Document | Current version | What it supports |
|---|---|---|
| COA | USCL 073125 | Lot-level quality-control and purity documentation; review the current COA for the reported batch result. |
| HPLC | USCL 073125 | Chromatographic purity and peak-profile context. |
| MS | USCL 073125 | Mass-spectrometry identity support for the modified peptide. |
Semaglutide 2mg 5 Vials Certificate of Analysis — USCL 073125
Lot-level quality-control and purity documentation.
Semaglutide 2mg 5 Vials HPLC Chromatogram — USCL 073125
Chromatographic purity and peak-profile context.
Semaglutide 2mg 5 Vials Mass Spectrometry Document — USCL 073125
Mass-spectrometry identity-support documentation.
Complete Technical Specifications
| Common name | Semaglutide |
|---|---|
| Alternative names | NNC 0113-0212 |
| Compound type | Synthetic acylated GLP-1 analog |
| Amino acid length | 31 residues with structural modifications |
| Structural features | Aib substitution, amino-acid substitution at position 34, and C18 fatty-diacid side chain |
| CAS number | 910463-68-2 |
| Molecular formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular weight | 4,113.58 g/mol |
| PubChem CID | 56843331 |
| Appearance | White to off-white lyophilized peptide powder or compact cake. |
| Storage context | Store refrigerated at 2–8°C unless product label, COA, or laboratory protocol specifies otherwise; protect from light, moisture, and unnecessary temperature cycling. |
Educational Insights: Understanding Peptide Quality
This section explains how to think about peptide quality without repeating the batch documents above. Quality review is not one number; it combines identity, purity, batch traceability, documentation, storage, and handling context.
Purity is useful, but not complete
A high HPLC purity figure should be read with the chromatogram, COA, and identity-support documents. Purity alone does not prove identity, lot traceability, labeling consistency, storage history, or handling controls.
Lyophilized format and handling context
Lyophilization removes water under controlled conditions to create a dry peptide material format for storage and transport. In laboratory settings, solvent selection, container geometry, peptide concentration, and buffer systems can influence observed dissolution behavior. This is research-preparation context, not use guidance.
Documentation workflow
A practical review flow is: confirm product identity and batch; read the COA; inspect the HPLC chromatogram; review MS or LC-MS/MS identity context; then preserve the documents in the laboratory record.
Frequently Asked Questions
What is Semaglutide 2mg 5 Vials?
It is a research-only package containing five lyophilized vials labelled 2mg per vial.
What type of peptide is Semaglutide?
It is a modified, acylated GLP-1 receptor agonist peptide.
What PubChem identifier is listed?
PubChem lists Semaglutide as CID 56843331.
Which batch documents are available?
The page displays a COA, HPLC chromatogram, and MS document, all labelled USCL 073125.
What does HPLC show?
HPLC provides chromatographic purity and related-component context under the stated method.
What is MS used for?
Mass spectrometry supports identity review of the modified peptide.
Why are both HPLC and MS useful?
HPLC supports purity context, while MS supports molecular-identity context.
Why is a batch-specific COA important?
It links the product to a lot, test date, reported purity, and supporting records.
How is Semaglutide supplied?
As lyophilized peptide material in five sealed 2mg vials.
What does lyophilized mean?
It refers to freeze-drying under controlled conditions to produce dry peptide material.
Can analytical documents predict a clinical result?
No. They support identity, purity, and batch review but do not establish clinical performance.
Does this page provide dosing or human-use guidance?
No. It provides no dosing, administration, clinical, veterinary, or human-use guidance.
Is Semaglutide the same as native GLP-1?
No. It is a modified analog designed for greater stability and albumin association.
Has Semaglutide been studied in humans?
Yes, extensively in controlled trials using regulated pharmaceutical formulations.
Do those trials validate research-market material?
No. Independent material requires its own identity, purity, formulation, and traceability evidence.
What are the main analytical concerns?
Modified-sequence identity, acylation, related peptides, degradation products, purity, potency, sterility, and batch traceability.
Selected Scientific References
These references provide research context and should be interpreted according to formulation, population, protocol, endpoint, and limitations.
- PMID 29651726 — cardiovascular outcomes trial.
- PMID 33567185 — randomized obesity trial.
- PMID 37952131 — cardiovascular outcomes in overweight or obesity.
- PubChem CID 56843331 — compound identity, formula, and molecular-weight record.
Clinical publications do not authenticate or validate a separately manufactured research batch.
